Clinical trials: Mild to Moderate Psoriasis
Psoriasis
A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis
Proof-of concept study to competitively investigate antipsoriatic efficacy and safety of a LAS41004 formulation vs active control No formal study hypothesis, but descriptive evaluation (PoC).
- Trial name
- Left/Right (NCT02180464)
- Testing
- LAS41004, control
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
The purpose of this study is to evaluate the therapeutic efficacy and safety of DSXS compared to a Placebo (vehicle) in patients with mild to moderate plaque psoriasis.
- Trial name
- NCT02618759
- Testing
- DSXS
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis Vulgaris
This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating the efficacy, safety and convenience of the MC2-01 cream.
- Trial name
- NCT03802344
- Testing
- MC2-01 cream, Cal/BDP combination, Vehicle
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 498 people
- Sponsor
- MC2 Therapeutics
Psoriasis Vulgaris
Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients
In this study, the safety, tolerability and efficacy of DLX105 administered topically onto the psoriatic lesion of mild-to-moderate psoriasis patients will be investigated.
- Trial name
- NCT01936337
- Testing
- DLX105 Hydrogel
- Where
- 3 sites in Austria, Germany
- Volunteers
- 59 people
- Sponsor
- Delenex Therapeutics AG
Psoriasis
Psoriasis、Indigo Naturalis、Chinese Medicine Medicated Bath
Psoriasis is a chronic inflammatory skin disease. Plague-type psoriasis is the most common form of the disease, occurring in more than 80% of the cases.
- Trial name
- NCT04117919
- Testing
- paper mulberry leaf, Triamcinolone (Encort-A) 0.1%15g/Tube
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Mild to Moderate Psoriasis
Topical Application of AS101 for the Treatment of Psoriasis
This protocol relates to a phase II randomized double blind, placebo controlled study of the AS101 topical application for the treatment of mild to moderate Psoriasis.
- Trial name
- NCT00788424
- Testing
- AS101 Cream
- Where
- Israel
- Sponsor
- BioMAS Ltd
Psoriasis
Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.
- Trial name
- NCT02801435
- Testing
- 0.5% Icotinib hydrochloride cream, 1.0% Icotinib hydrochloride cream, 2.0% Icotinib hydrochloride cream
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Plaque Psoriasis
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
- Trial name
- NCT06088199
- Testing
- Apremilast
- Where
- 30 sites in United States
- Volunteers
- 51 people
- Sponsor
- Amgen
Mild to Moderate Psoriasis
A Phase III Study in Subjects With Mild to Moderate Psoriasis.
A randomized, assessor blind, parallel group, three arms, active and placebo controlled study with objective to demonstrate therapeutic non-inferiority of AKP02 cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/…
- Trial name
- AKVANO-AKP02 (NCT05249972)
- Testing
- AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO), Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
- Where
- India
- Volunteers
- 294 people
- Sponsor
- Lipidor AB
Psoriasis, Plaque Psoriasis
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.
- Trial name
- NCT04603027
- Testing
- EDP1815
- Where
- 29 sites in United States, Hungary and 2 more
- Volunteers
- 249 people
- Sponsor
- Evelo Biosciences, Inc.
Plaque Psoriasis
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
This Phase 2 study has been designed to determine and compare the safety, tolerability, and efficacy of DUR-928 topical solution with that of the vehicle topical solution when applied once daily for approximately four weeks in…
- Trial name
- NCT03837743
- Testing
- DUR-928 Topical Solution, Vehicle Topical Solution
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Durect
Psoriasis
A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris.
A multi-center, randomized, single blind, positive controlled trials that assess the effectiveness, safety and cost-effectiveness analysis in patients with mild to moderate psoriasis vulgaris and compare Compound Clobetasol…
- Trial name
- NCT02733874
- Testing
- Compound Clobetasol Propionate Ointment, Calcipotriol Betamethasone Ointment
- Volunteers
- 240 people
- Sponsor
- First Hospital of China Medical University
Psoriasis
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis.
- Trial name
- NCT05642182
- Testing
- SFA002
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- SFA Therapeutics
Psoriasis
Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject
To evaluate the safety and tolerability of UCB5857. Part 1 of the study explores single doses of the drug. Part 2 of the study explores giving the drug every day for 14 days. The study uses healthy and psoriasis subjects.
- Trial name
- NCT02303509
- Testing
- UCB5857 Part 1, UCB5857 Part 2
- Where
- United Kingdom
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Mild to Moderate Psoriasis, Healthy Volunteers
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.
The purpose of the study is to evaluate the safety and pharmacokinetics of UCB0159 administered in participants with mild to moderate plaque psoriasis and evaluate single dose pharmacokinetics and safety of UCB0159 in healthy…
- Trial name
- NCT07849894
- Testing
- UCB0159
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Psoriasis
Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam
The purpose of the study is to compare the efficacy and safety of Clobetasol propionate to that of its Vehicle in the treatment of mild to moderate plaque-type psoriasis.
- Trial name
- NCT00842153
- Testing
- Clobetasol propionate foam, Vehicle foam
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Stiefel, a GSK Company
Mild to Moderate Psoriasis
Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)
A Topical Treatment Optimisation Programme (TTOP) has been developed by the sponsor together with Patient Boards and an Expert Advisory Board to overcome non-adherence problems.
- Trial name
- PSO-TOP (NCT01587755)
- Testing
- TTOP, non-TTOP
- Where
- 93 sites in Denmark, France and 6 more
- Volunteers
- 1,852 people
- Sponsor
- Kristian Reich, MD
Psoriasis
AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis
The purpose of this study is to determine whether AN2728 topical ointment is a safe and effective treatment for mild-to-moderate plaque-type psoriasis.
- Trial name
- NCT01300052
- Testing
- AN2728 ointment, 2%, Ointment Vehicle
- Where
- 10 sites in United States
- Volunteers
- 68 people
- Sponsor
- Pfizer
Psoriasis, Healthy
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people.
- Trial name
- NCT07850310
- Testing
- MK-8644
- Where
- Australia
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients
This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib Hydrochloride Cream in healthy adults and patients with mild to moderate psoriasis.
- Trial name
- NCT02574091
- Testing
- 1% icotinib hydrochloride cream, 2% icotinib hydrochloride cream
- Where
- New Zealand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.